Stefan O SchÃ¶nland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4719228/publications.pdf

Version: 2024-02-01

240	8,694	57758	54911
papers	citations	44 h-index	84 g-index

256	256	256	6858
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	1.6	735
2	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	1.4	385
3	A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood, 2014, 124, 2325-2332.	1.4	366
4	Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38.	30.5	350
5	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	27.0	268
6	Longitudinal Left Ventricular Function for Prediction of Survival in Systemic Light-Chain Amyloidosis. Journal of the American College of Cardiology, 2012, 60, 1067-1076.	2.8	253
7	Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm, 2008, 5, 235-240.	0.7	214
8	Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood, 2012, 119, 488-493.	1.4	200
9	Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13471-13476.	7.1	185
10	Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. Journal of Clinical Oncology, 2015, 33, 1371-1378.	1.6	185
11	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology, 2016, 34, 1097-1103.	1.6	176
12	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood, 2013, 121, 5055-5063.	1.4	171
13	Homeostatic control of T-cell generation in neonates. Blood, 2003, 102, 1428-1434.	1.4	158
14	Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nature Communications, 2019, 10, 1103.	12.8	120
15	Hereditary Apolipoprotein AI-Associated Amyloidosis in Surgical Pathology Specimens. Journal of Molecular Diagnostics, 2009, 11, 257-262.	2.8	116
16	In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain, 2015, 138, 549-562.	7.6	112
17	Non-invasive predictors of survival in cardiac amyloidosis. European Journal of Heart Failure, 2007, 9, 617-624.	7.1	109
18	Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood, 2010, 116, 2455-2461.	1.4	109

#	Article	IF	Citations
19	Polymorphism of Amyloid Fibrils In Vivo. Angewandte Chemie - International Edition, 2016, 55, 4822-4825.	13.8	109
20	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 2017, 130, 597-605.	1.4	108
21	Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Human Mutation, 2009, 30, 1567-1573.	2.5	107
22	AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood, 2017, 130, 632-642.	1.4	104
23	Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood, 2008, 111, 4700-4705.	1.4	103
24	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. Journal of Clinical Oncology, 2020, 38, 3252-3260.	1.6	102
25	Amyloid in biopsies of the gastrointestinal tractâ€"a retrospective observational study on 542 patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 569-577.	2.8	93
26	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. Clinical Research in Cardiology, 2019, 108, 1324-1330.	3.3	93
27	Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 2010, 116, 522-528.	1.4	84
28	Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 9-17.	3.0	84
29	Postallograft lenalidomide induces strong NK cellâ€"mediated antimyeloma activity and risk for T cellâ€"mediated GvHD: Results from a phase I/II dose-finding study. Experimental Hematology, 2013, 41, 134-142.e3.	0.4	83
30	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica, 2018, 103, 514-521.	3.5	70
31	Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. Nature Communications, 2021, 12, 875.	12.8	70
32	Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood, 2016, 128, 594-602.	1.4	67
33	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood, 2020, 135, 1517-1530.	1.4	67
34	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. Journal of Heart and Lung Transplantation, 2018, 37, 611-618.	0.6	66
35	High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. British Journal of Haematology, 2004, 127, 543-551.	2.5	62
36	Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood, 2006, 107, 2578-2584.	1.4	62

#	Article	IF	Citations
37	Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica, 2008, 93, 459-462.	3.5	62
38	SjÃ¶gren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?. Arthritis and Rheumatism, 2008, 58, 1992-1999.	6.7	61
39	Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood, 2011, 117, 3809-3815.	1.4	60
40	Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways Inâ€…Vivo. Angewandte Chemie - International Edition, 2017, 56, 7510-7514.	13.8	59
41	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 2021, 11, 10.	6.2	53
42	Rapid Progression of Left Ventricular Wall Thickness Predicts Mortality in Cardiac Light-chain Amyloidosis. Journal of Heart and Lung Transplantation, 2007, 26, 1313-1319.	0.6	52
43	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2134-2142.	2.0	52
44	Amyloid in endomyocardial biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 523-532.	2.8	50
45	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 1-2.	3.0	49
46	Sural nerve injury in familial amyloid polyneuropathy. Neurology, 2017, 89, 475-484.	1.1	48
47	Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac lightâ€chain amyloidosis. European Journal of Heart Failure, 2009, 11, 1014-1020.	7.1	45
48	Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplantation, 2008, 41, 779-784.	2.4	44
49	Rapid assessment of longitudinal systolic left ventricular function using speckle tracking of the mitral annulus. Clinical Research in Cardiology, 2012, 101, 273-280.	3.3	43
50	Prevalence of Germline Mutations in the TTR Gene in a Consecutive Series of Surgical Pathology Specimens With ATTR Amyloid. American Journal of Surgical Pathology, 2009, 33, 58-65.	3.7	39
51	Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica, 2017, 102, 1424-1431.	3.5	39
52	Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplantation, 2012, 47, 895-905.	2.4	37
53	Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. International Journal of Cardiology, 2013, 164, 179-184.	1.7	37
54	Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate. Journal of Biological Chemistry, 2017, 292, 2328-2344.	3.4	37

#	Article	IF	Citations
55	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2016, 128, 646-646.	1.4	37
56	Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM. Nature Communications, 2021, 12, 6434.	12.8	36
57	The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Annals of Oncology, 2014, 25, 200-206.	1.2	35
58	Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica, 2007, 92, 1513-1518.	3.5	34
59	Prognosis and Staging of AL Amyloidosis. Acta Haematologica, 2020, 143, 388-400.	1.4	34
60	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139.	1.4	34
61	Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. Bone Marrow Transplantation, 2015, 50, 1279-1285.	2.4	33
62	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Advances, 2018, 2, 2607-2618.	5.2	33
63	Fatal amyloid formation in a patientâ€™s antibody light chain is caused by a single point mutation. ELife, 2020, 9, .	6.0	33
64	Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood Cancer Journal, 2017, 7, e537-e537.	6.2	32
65	Myocardial contraction fraction derived from cardiovascular magnetic resonance cine imagesâ€”reference values and performance in patients with heart failure and left ventricular hypertrophy. European Heart Journal Cardiovascular Imaging, 2017, 18, 1414-1422.	1.2	32
66	Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia, 2017, 31, 1735-1742.	7.2	32
67	CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myelomaâ€”Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Frontiers in Immunology, 2018, 9, 1676.	4.8	32
68	The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Annals of Hematology, 2018, 97, 1241-1250.	1.8	31
69	Local vs. systemic pulmonary amyloidosisâ€”impact on diagnostics and clinical management. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 627-637.	2.8	31
70	Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplantation, 2020, 55, 1810-1816.	2.4	31
71	First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. Blood, 2018, 131, 368-371.	1.4	30
72	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood, 2018, 132, 1988-1991.	1.4	30

#	Article	IF	Citations
73	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica, 2019, 104, 1451-1459.	3.5	29
74	Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Annals of Hematology, 2021, 100, 2087-2093.	1.8	29
75	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	7.2	29
76	Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer Journal, 2018, 8, 101.	6.2	28
77	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica, 2019, 104, 2274-2282.	3.5	27
78	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166.	1.4	27
79	Centre characteristics and procedureâ€related factors have an impact on outcomes of allogeneic transplantation for patients with <scp>CLL</scp>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). British Journal of Haematology, 2017, 178, 521-533.	2.5	26
80	Flow cytometryâ€based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. Cancer Medicine, 2016, 5, 1464-1472.	2.8	25
81	Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 53.	3.3	25
82	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. American Journal of Hematology, 2020, 95, 1158-1169.	4.1	25
83	Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 243-251.	3.0	25
84	Risk factors for AA amyloidosis in Germany. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 1-7.	3.0	24
85	Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 37-45.	3.0	24
86	MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis. Neurology, 2018, 91, e625-e634.	1.1	24
87	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 8-13.	3.0	24
88	Risk Stratification in Cardiac Amyloidosis: Novel Approaches. Transplantation, 2005, 80, S151-S155.	1.0	23
89	Familial Mediterranean fever in Germany: clinical presentation and amyloidosis risk. Scandinavian Journal of Rheumatology, 2013, 42, 52-58.	1.1	23
90	Cerebral amyloid angiopathy â€“ an underdiagnosed entity in younger adults with lobar intracerebral hemorrhage?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 45-47.	3.0	22

#	Article	IF	Citations
91	Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre. International Journal of Cardiovascular Imaging, 2017, 33, 879-888.	1.5	22
92	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 3-17.	3.0	22
93	Three German fibrinogen AÎ±-chain amyloidosis patients with the p.Glu526Val mutation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 25-31.	2.8	21
94	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. Frontiers in Immunology, 2018, 9, 2207.	4.8	21
95	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 1372-1378.	2.0	20
96	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e493-e499.	0.4	20
97	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 231-236.	3.0	20
98	Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis. Annals of Clinical and Translational Neurology, 2020, 7, 799-807.	3.7	20
99	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. Blood, 2010, 116, 1364-1364.	1.4	19
100	Indications for High-Dose Chemotherapy with Autologous Stem Cell Support in Patients with Systemic Amyloid Light Chain Amyloidosis. Transplantation, 2005, 80, S160-S163.	1.0	18
101	Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 52-59.	3.0	18
102	Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica, 2018, 103, 336-343.	3.5	18
103	Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a singleâ€center analysis. Clinical Transplantation, 2013, 27, 40-48.	1.6	17
104	Allogeneic Transplantation in Multiple Myelomaâ€”Does It Still Have a Place?. Journal of Clinical Medicine, 2020, 9, 2180.	2.4	17
105	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357.	2.5	17
106	Indications for Liver Transplantation in Patients with Amyloidosis: A Single-Center Experience with 11 Cases. Transplantation, 2005, 80, S156-S159.	1.0	16
107	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplantation, 2015, 50, 505-510.	2.4	16
108	Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. Frontiers in Immunology, 2019, 10, 547.	4.8	16

#	Article	IF	Citations
109	Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 202-210.	3.0	15
110	Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 45-53.	3.0	15
111	Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. Haematologica, 2017, 102, 1281-1290.	3.5	15
112	AL amyloidosis with a localized B cell neoplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 353-363.	2.8	15
113	Seeded fibrils of the germline variant of human Î»-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability. Journal of Biological Chemistry, 2020, 295, 18474-18484.	3.4	15
114	Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. Haematologica, 2008, 93, 955-956.	3.5	14
115	Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 1712-1721.	7.0	14
116	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. Biology of Blood and Marrow Transplantation, 2017, 23, 1193-1202.	2.0	14
117	Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. Hematological Oncology, 2018, 36, 210-216.	1.7	14
118	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. Cytometry Part B - Clinical Cytometry, 2017, 92, 145-152.	1.5	13
119	Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma. Cytometry Part B - Clinical Cytometry, 2018, 94, 767-776.	1.5	13
120	A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clinical Research in Cardiology, 2020, 109, 700-713.	3.3	13
121	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. Leukemia, 2020, 34, 1187-1191.	7.2	13
122	<scp>Daratumumab, lenalidomide, and dexamethasone</scp> in systemic <scp>lightâ€chain</scp> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American Journal of Hematology, 2021, 96, E253-E257.	4.1	13
123	Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. European Journal of Haematology, 2021, 107, 449-457.	2.2	13
124	Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Leukemia, 2014, 28, 2254-2256.	7.2	12
125	Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis. Journal of Cardiovascular Magnetic Resonance, 2017, 19, 87.	3.3	12
126	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. Blood, 2020, 136, 50-51.	1.4	12

#	Article	IF	Citations
127	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. Blood, 2012, 120, 731-731.	1.4	12
128	Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis. Journal of the American Society of Echocardiography, 2016, 29, 1188-1196.	2.8	11
129	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Biology of Blood and Marrow Transplantation, 2018, 24, 930-936.	2.0	11
130	Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from aÂlarge cohort of patients with long followâ€up. British Journal of Haematology, 2021, 195, 230-243.	2.5	11
131	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 2120-2120.	1.4	11
132	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. Blood, 2020, 136, 48-50.	1.4	11
133	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2014, 124, 35-35.	1.4	11
134	Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways Inâ€…Vivo. Angewandte Chemie, 2017, 129, 7618-7622.	2.0	10
135	Treosulfan conditioning for allogeneic transplantation in multiple myeloma â€“ improved overall survival in first line haematopoietic stem cell transplantation â€“ a large retrospective study by the Chronic Malignancies Working Party of the EBMT. British Journal of Haematology, 2020, 189, e213-e217.	2.5	10
136	Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. PLoS ONE, 2022, 17, e0264407.	2.5	10
137	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 56-57.	3.0	9
138	Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 1870-1878.	2.0	9
139	CT features in amyloidosis of the respiratory system â€“ Comprehensive analysis in a tertiary referral center cohort. European Journal of Radiology, 2020, 129, 109123.	2.6	9
140	Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2016, 128, 993-993.	1.4	9
141	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. Vaccines, 2022, 10, 330.	4.4	9
142	Solid state NMR assignments of a human Î»-III immunoglobulin light chain amyloid fibril. Biomolecular NMR Assignments, 2021, 15, 9-16.	0.8	8
143	Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 91-99.	3.0	8
144	CD4+CD25highCD127low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. Scientific World Journal, The, 2012, 2012, 1-10.	2.1	7

#	Article	IF	Citations
145	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq1 1 0.784314 rgBT /Ove	1.3	7
146	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Haematologica, 2017, 102, e411-e414.	3.5	7
147	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2823-2834.	2.5	7
148	Conditioningâ€based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991â€2012) on behalf of EBMT CMWP. European Journal of Haematology, 2020, 104, 181-189.	2.2	7
149	Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis. Hematology/Oncology Clinics of North America, 2020, 34, 1133-1144.	2.2	7
150	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. Bone Marrow Transplantation, 2021, 56, 210-217.	2.4	7
151	Ixazomib-dexamethasone (Ixa-Dex) vs physicianâ€™s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology, 2020, 38, 8546-8546.	1.6	7
152	Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells. Cytotherapy, 2022, 24, 311-319.	0.7	7
153	Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. International Journal of Cardiology, 2014, 176, 1113-1115.	1.7	6
154	<scp>CD</scp>7 is expressed on a subset of normal <scp>CD</scp>34â€positive myeloid precursors. European Journal of Haematology, 2018, 101, 318-325.	2.2	6
155	New sequence variants in patients affected by amyloidosis show transthyretin instability by isoelectric focusing. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 85-93.	3.0	6
156	Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. Biology of Blood and Marrow Transplantation, 2020, 26, 1559-1566.	2.0	6
157	Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2021, 27, 999.e1-999.e10.	1.2	6
158	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	1.4	6
159	Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect". Haematologica, 2009, 94, 439-441.	3.5	5
160	Search for AL amyloidosis risk factors using Mendelian randomization. Blood Advances, 2021, 5, 2725-2731.	5.2	5
161	AL Amyloidosis â€" Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells. Blood, 2018, 132, 187-187.	1.4	5
162	Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. Blood, 2020, 136, 37-40.	1.4	5

#	Article	IF	Citations
163	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. Blood, 2011, 118, 995-995.	1.4	5
164	Treatment of AL Amyloidosis with Bendamustine. Blood, 2012, 120, 4057-4057.	1.4	5
165	Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP) Tj ETQq1 1 0.784314 rgBT /Ov	1.4	5
166	Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. Journal of Clinical Oncology, 2018, 36, 8011-8011.	1.6	5
167	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	1.4	5
168	Dual-Echo Turbo Spin Echo and 12-Echo Multi Spin Echo Sequences as Equivalent Techniques for Obtaining T2-Relaxometry Data. Investigative Radiology, 2022, 57, 301-307.	6.2	5
169	Lysozyme amyloidosisâ€"a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 245-254.	3.0	5
170	Doxycycline in ATTRY69H (p.ATTRY89H) amyloidosis with predominant leptomeningeal manifestation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 279-280.	3.0	4
171	Ruxolitinib is effective in the treatment of a patient with refractory Tâ€ALL. EJHaem, 2021, 2, 139-142.	1.0	4
172	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2019, 134, 3163-3163.	1.4	4
173	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	1.4	4
174	Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantationâ€"study on behalf of CMWP of the EBMT. Bone Marrow Transplantation, 2022, 57, 633-640.	2.4	4
175	Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. Bone Marrow Transplantation, 2022, 57, 817-823.	2.4	4
176	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine, 2022, 11, 3541.	2.4	4
177	Identification of AL proteins from 10 Î»-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 27-37.	3.0	4
178	Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. Clinical Research in Cardiology, 2021, 110, 579-590.	3.3	3
179	Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 3425-3425.	1.4	3
180	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. Blood, 2019, 134, 4575-4575.	1.4	3

#	Article	IF	Citations
181	Detection and Characterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry. Blood, 2014, 124, 2068-2068.	1.4	3
182	Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT. Blood, 2014, 124, 2561-2561.	1.4	3
183	Two-Year Evaluation of the German Clinical Amyloidosis Registry. Blood, 2021, 138, 3780-3780.	1.4	3
184	Healthâ€related quality of life in patients with <scp>light chain</scp> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasoneâ€‰Â±â€‰daratumumab: Results from the <scp>ANDROMEDA</scp> study. American Journal of Hematology, 2022, 97, 719-730.	4.1	3
185	Reply to R. Warsame et al. Journal of Clinical Oncology, 2015, 33, 3976-3977.	1.6	2
186	Flow in a fibril-forming disease. Blood, 2017, 129, 7-8.	1.4	2
187	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 686-693.	0.4	2
188	Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up. Blood, 2019, 134, 259-259.	1.4	2
189	Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT. Blood, 2019, 134, 324-324.	1.4	2
190	Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation. Blood, 2010, 116, 2376-2376.	1.4	2
191	Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma. An EBMT Analysis. Blood, 2013, 122, 920-920.	1.4	2
192	Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis. Blood, 2015, 126, 1790-1790.	1.4	2
193	The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Blood, 2015, 126, 3223-3223.	1.4	2
194	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. Blood, 2016, 128, 2293-2293.	1.4	2
195	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. Blood, 2016, 128, 3499-3499.	1.4	2
196	The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.. Journal of Clinical Oncology, 2016, 34, TPS8073-TPS8073.	1.6	2
197	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 2143-2143.	1.4	2
198	Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 129-136.	3.0	1

#	Article	IF	Citations
199	Therapy of AL amyloidosis â€“ work-up and treatment at our centre. Memo - Magazine of European Medical Oncology, 2012, 5, 18-22.	0.5	1
200	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	1.6	1
201	Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2021, 56, 529-531.	2.4	1
202	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation, 2021, 56, 2367-2381.	2.4	1
203	Submyeloablative total body irradiationâ€based conditioning and allogeneic stem cell transplantation in highâ€risk myeloma with early progression after upâ€front autologous transplantation. British Journal of Haematology, 2021, , .	2.5	1
204	Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.. Blood, 2007, 110, 2500-2500.	1.4	1
205	Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.. Blood, 2009, 114, 3401-3401.	1.4	1
206	Efficacy and Toxicity of Dose-Reduced Bortezomib/Dexamethasone Chemotherapy In Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III). Blood, 2010, 116, 1960-1960.	1.4	1
207	Hyperdiploidy Is Rare in Patients with AL Amyloidosis â€“ Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.. Blood, 2009, 114, 2823-2823.	1.4	1
208	Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex). Blood, 2013, 122, 1993-1993.	1.4	1
209	Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis. Blood, 2013, 122, 417-417.	1.4	1
210	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. Blood, 2018, 132, 3399-3399.	1.4	1
211	Systemic Light Chain Amyloidosis. , 2019, , 609-614.		1
212	Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 4574-4574.	1.4	1
213	Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone. Blood, 2020, 136, 17-18.	1.4	1
214	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation, 2022, , .	2.4	1
215	Treatment in AL Amyloidosis: Moving towards Individualized and Clone-Directed Therapy. Hemato, 2021, 2, 739-747.	0.6	1
216	Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis. HemaSphere, 2022, 6, e688.	2.7	1

#	Article	IF	Citations
217	Amyloidogenicity of Immunoglobulin Light Chains. Biophysical Journal, 2015, 108, 386a.	0.5	0
218	Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 68-69.	3.0	0
219	Optimizing Outcomes after Heart Transplantation in Patients with Cardiac Amyloidosis - A Single Center Analysis of 48 Patients in 2 Eras. Journal of Heart and Lung Transplantation, 2018, 37, S92.	0.6	0
220	DUAL expectations in light chain amyloidosis. EClinicalMedicine, 2020, 24, 100461.	7.1	0
221	Prognostic impact of earlyâ€versusâ€late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. European Journal of Haematology, 2021, 106, 708-715.	2.2	0
222	High-Dose Melphalan Chemotherapy with Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: No Increased Mortality Using Induction and Mobilization Chemotherapy.. Blood, 2005, 106, 5505-5505.	1.4	0
223	Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.. Blood, 2006, 108, 3018-3018.	1.4	0
224	Defective Telomerase in Familial Myelodysplasia and Leukemia. Blood, 2008, 112, 849-849.	1.4	0
225	Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,. Blood, 2011, 118, 3946-3946.	1.4	0
226	Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,. Blood, 2011, 118, 4124-4124.	1.4	0
227	Low Pre-Transplant Levels of 25-Hydroxyvitamin D3 Predict Relapse and Survival in Male but Not in Female Patients Undergoing Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1181-1181.	1.4	0
228	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. Blood, 2015, 126, 3049-3049.	1.4	0
229	Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice: a Single Center Experience. Blood, 2016, 128, 5686-5686.	1.4	0
230	Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients. Blood, 2018, 132, 3264-3264.	1.4	0
231	High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia. Blood, 2019, 134, 3077-3077.	1.4	0
232	A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations. Blood, 2019, 134, 3379-3379.	1.4	0
233	Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy. Blood, 2019, 134, 3287-3287.	1.4	0
234	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. Blood, 2021, 138, 4771-4771.	1.4	0

#	Article	IF	Citations
235	Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT. Blood, 2021, 138, 485-485.	1.4	0
236	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). Blood, 2021, 138, 1810-1810.	1.4	0
237	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT. Blood, 2020, 136, 26-27.	1.4	0
238	Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT. Blood, 2020, 136, 1-2.	1.4	0
239	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. Blood, 2020, 136, 11-11.	1.4	0
240	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. Blood, 2020, 136, 33-34.	1.4	0